Celldex Therapeutics (CLDX) Change in Accured Expenses (2010 - 2026)

Celldex Therapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$1.4 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 84.42% year-over-year to -$1.4 million; the TTM figure through Mar 2026 stood at $6.6 million (up 50.67% YoY), while the FY2025 annual figure was -$753000.0, down 106.47% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.4 million, up from -$7.2 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $13.1 million in Q3 2025, with the low at -$8.7 million in Q1 2025.
• The 5-year median for Change in Accured Expenses is -$387000.0 (2022), against an average of $1.3 million.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses surged 6041.73% in 2023, then slumped 493.46% in 2025.
• Celldex Therapeutics' Change in Accured Expenses stood at -$139000.0 in 2022, then soared by 6041.73% to $8.3 million in 2023, then retreated by 3.21% to $8.0 million in 2024, then sank by 189.85% to -$7.2 million in 2025, then jumped by 81.09% to -$1.4 million in 2026.
• Business Quant data shows CLDX's Change in Accured Expenses at -$1.4 million in Q1 2026, -$7.2 million in Q4 2025, and $13.1 million in Q3 2025.